We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:99% up by HPLC Levetiracetam 102767-28-2 CAS No.:102767-28-2 Standard:ChP Price(USD):Negotiable Company:Sinoway Industrial Co.Ltd.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Monthly Production Capacity: 10tons/year
Contract Manufacturing: CRO,CMO
Packaging Information: 25kg/bag
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/C
Product name
Levetiracetam
CAS No.
102767-28-2
Molecular Formula
C4H11NO
Molecular Weight
170.211
Quality Standard
98% up by HPLC
Appearance
White or almost white powder
COA
ANALYSIS
SPECIFICATION
RESULTS
Appearance
White or almost white powder
White powder
Assay
98.0% - 102.0%
99.2%
Water
≤ 0.5%
≤ 0.1%
Residue on ignition
≤ 0.1%
≤ 0.1%
Heavy metals
≤ 20ppm
< 20ppm
Enantiomeric purity
≤ 0.8%
Not detected
Conclusion
The sample complies with the USP standard.
Usage
Levetiracetam is a medication primarily used to treat certain types of seizures in patients with epilepsy. It is a white crystalline powder with a specific chemical structure, namely (S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, and has a molecular formula of C8H14N2O2.
Levetiracetam functions primarily as an anticonvulsant drug, which means it is designed to prevent or reduce the frequency and severity of seizures in patients with epilepsy. The exact mechanism of action of Levetiracetam is believed to work by binding to a protein called synaptic vesicle protein 2A (SV2A) located in the presynaptic terminal of neurons. This binding is thought to interfere with the release of neurotransmitters, specifically glutamate, which is involved in the generation and spread of seizures. By modulating glutamate release, Levetiracetam can reduce the likelihood of seizures occurring.